Why the study?
This study evaluates the effects of Ginkgo biloba extract monotherapy on glycemic status, insulin resistance, BMI, VAI, inflammatory markers, oxidative status, and leptin level in patients with metabolic syndrome compared with metformin.
Does Ginkgo biloba extract improve glycemic status, insulin resistance, and anthropometric measures in patients with metabolic syndrome compared to metformin?
Does Ginkgo biloba extract improve glycemic status, insulin resistance, and anthropometric measures in patients with metabolic syndrome compared to metformin?
Ginkgo biloba extract 120 mg daily for 90 days improved insulin resistance, BMI, visceral adiposity, and inflammatory markers in patients with metabolic syndrome, suggesting potential as a monotherapy.
Ginkgo biloba monotherapy may improve metabolic parameters in MetS; leaves open comparative efficacy versus metformin in larger trials.
The present study evaluates the effects of Ginkgo biloba extract as monotherapy on the glycemic status, insulin resistance (IR), body mass index (BMI), and visceral adiposity index (VAI), in addition to the inflammatory markers, oxidative status and leptin level in patients with metabolic syndrome in comparison with metformin. The study is a randomized, double-blind pilot study conducted during the period May to September, 2020. Fifty patients were recruited in the study and they were allocated into two groups (25 per each group): Ginkgo biloba and Metformin groups, they received (120 mg Ginkgo biloba extract/ capsule) and (500 mg Metformin/ capsule) respectively; orally as a single dose for 90 days. Blood samples were taken at zero time and after 90 days and utilized for analysis of blood glucose, HbA1c, insulin and leptin levels, lipid profile, TAOS, hsCRP, TNF
No takes yet. Share an insight, caveat, or question.
Tavga Ahmed Aziz (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: